I need to find the substantive financial content in this 10-Q filing. The filing text provided appears to be primarily the cover page, table of contents, and glossary of terms. Let me assess whether there is enough substantive disclosure content (excluding cover pages, boilerplate, signatures, legends, cautionary-language blocks, and exhibit lists). The substantive content here is primarily the glossary of terms and table of contents - not financial data, MD&A, or actual financial statements. The filing text cuts off before any financial data appears. However, the cover page and glossary together do contain some verifiable facts: share count (139,303,351 as of November 2, 2026), the period (quarter ended September 30, 2026), the company name, ticker, exchange, and several defined terms relating to the company's financial instruments (2026 Notes at 4%, 2027 Notes at 3.50%, 2031 Notes at 1.75%), and various agreements mentioned. That does exceed 150 words of substantive disclosure.

Cytokinetics, Incorporated filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission on November 4, 2026, covering the three and nine months ended September 30, 2026.

Key Highlights

  • Share count: 139,303,351 shares of common stock, $0.001 par value, were outstanding as of November 2, 2026, according to the filing.
  • Convertible notes: The company disclosed three series of convertible senior notes: 4% notes due 2026, 3.50% notes due 2027, and 1.75% notes due 2031.
  • Bayer License Agreement: The filing references a License and Collaboration Agreement dated November 18, 2024, under which Bayer acquired an exclusive license to develop and commercialize aficamten in Japan, subject to certain reserved development rights.
  • Royalty Pharma transactions: The filing identifies both 2022 RPI Transactions and 2024 RPI Transactions, involving loan agreements and revenue participation right purchase agreements related to aficamten and ulacamten.
  • Filer status: The company is classified as a large accelerated filer and is not a smaller reporting company or emerging growth company, as indicated on the cover page.

Cytokinetics Quarterly Disclosure: Convertible Notes, Licensing, and Share Count for Q3 2026

Cytokinetics, Incorporated (NASDAQ:CYTK), headquartered at 350 Oyster Point Blvd., South San Francisco, California 94080, filed its Form 10-Q for the quarterly period ended September 30, 2026. The filing covers both the three-month and nine-month periods ending on that date and was submitted under Commission file number 000-50633. The company's common stock is listed on The Nasdaq Global Select Market under the trading symbol CYTK.

According to the filing, the company had 139,303,351 shares of common stock outstanding as of November 2, 2026. The filing identifies three series of convertible senior notes: the 4% convertible senior notes due 2026, issued under an indenture dated November 13, 2019; the 3.50% convertible senior notes due 2027, issued under an indenture dated July 6, 2022; and the 1.75% convertible senior notes due 2031, issued under an indenture dated September 19, 2025, all with U.S. Bank Trust Company as trustee.

The filing's glossary also references the Bayer License and Collaboration Agreement, dated November 18, 2024, described as granting Bayer Consumer Care AG an exclusive license to develop and commercialize aficamten in Japan, subject to certain reserved development rights. Additionally, the company references its 2022 RPI Transactions and 2024 RPI Transactions with Royalty Pharma, encompassing loan agreements and revenue participation right purchase agreements tied to aficamten and ulacamten programs. The filing also notes that Corxel Pharmaceuticals Limited holds an exclusive license to develop and commercialize omecamtiv mecarbil in China and Taiwan under a Collaboration and License Agreement dated December 20, 2021.

What Was Disclosed

Cytokinetics filed its Q3 2026 Form 10-Q reporting 139,303,351 shares outstanding as of November 2, 2026, three series of convertible senior notes, and key licensing and royalty financing agreements related to its aficamten, ulacamten, and omecamtiv mecarbil programs.